| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/BMT.2017.228 |
| P698 | PubMed publication ID | 29131152 |
| P50 | author | Angela Dispenzieri | Q37838558 |
| Nelson Leung | Q42692816 | ||
| Eli Muchtar | Q57021390 | ||
| Morie A Gertz | Q57052163 | ||
| David Dingli | Q66385573 | ||
| Martha Q Lacy | Q66419394 | ||
| Francis K Buadi | Q88774336 | ||
| P2093 | author name string | R Chakraborty | |
| P Kapoor | |||
| S K Kumar | |||
| S R Hayman | |||
| W J Hogan | |||
| P2860 | cites work | Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis | Q24338918 |
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Interpretation of cytogenetic results in multiple myeloma for clinical practice | Q26777803 | ||
| A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. | Q33418036 | ||
| The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes | Q33573495 | ||
| Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation. | Q33660396 | ||
| How we manage autologous stem cell transplantation for patients with multiple myeloma | Q34019581 | ||
| Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma | Q34296442 | ||
| Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects | Q36083211 | ||
| Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma | Q36754816 | ||
| High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients | Q36838506 | ||
| Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group | Q36839385 | ||
| F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma | Q37348247 | ||
| Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. | Q38094334 | ||
| Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma | Q38395160 | ||
| Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. | Q41091821 | ||
| Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. | Q41947865 | ||
| Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative | Q43727656 | ||
| Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study | Q43821016 | ||
| Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. | Q46088678 | ||
| Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy. | Q46317416 | ||
| Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks. | Q52543923 | ||
| Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. | Q52860687 | ||
| Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation | Q58050916 | ||
| Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile | Q60203403 | ||
| The biology of interleukin-6 | Q69086773 | ||
| Correlation between the uptake of Tc-99m-sestaMIBI and prognostic factors in patients with multiple myeloma | Q74307263 | ||
| Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma | Q74476203 | ||
| Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans | Q79594356 | ||
| Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications | Q79766223 | ||
| Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial | Q82564216 | ||
| Treatment of relapsed and refractory multiple myeloma | Q88033741 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 155-161 | |
| P577 | publication date | 2017-11-13 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation | |
| P478 | volume | 53 |
| Q64113105 | Pretransplant C-reactive protein as a prognostic marker in allogeneic stem cell transplantation: A PRISMA-compliant meta-analysis | cites work | P2860 |
Search more.